Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

clinical health data

Driving Healthcare Decisions with Natural Language Processing

Dr. Sabita Sankar, VP of Business Development at HUMA.AI, discusses “human-centric AI” and how to automate healthcare through human language, with special focus on the applications for Medical Affairs, Clinical,...

Impetus Digital

- PMLiVE

Merck and Ridgeback request EUA from US FDA for COVID-19 drug molnupiravir

If authorised, molnupiravir could be the first oral antiviral medicine for the treatment of mild-to-moderate COVID-19 in at risk adults

- PMLiVE

Lupus Awareness Month

In this second October’s blog, we will be looking into Lupus in clinical trials: its symptoms, complications, treatments, incidence and focus on diversity.

Innovative Trials

- PMLiVE

Results of AstraZeneca’s TACKLE phase 3 trial show antibody combination reduces risk of severe COVID-19 or death

The antibody is the only long-acting combination shown to both prevent and treat COVID-19

The Real-Time Health System: Accelerating Workflows with Data

Bree Bush, Vice President, Chief Data Officer at GE Healthcare, dives into simulation modeling and advanced analytical tools to optimize inpatient, procedural, and clinic capacity; the concept of “real-time healthcare”;...

Impetus Digital

The Future of eHealth: Contactless Health Monitoring

Laurence Pearce, CEO & Founder of Xim Ltd, creators of Lifelight®, discusses the need for personal health monitoring; traditional issues associated with population health screening; AI, machine learning, and computer...

Impetus Digital

- PMLiVE

AstraZeneca requests Emergency Use Authorization from FDA for COVID-19 antibody

Phase 3 data shows the long-acting antibody combination produces a 77% reduction in the risk of developing symptomatic COVID-19

- PMLiVE

Black community representation in clinical trials

This Black History Month, we discuss the black representation in clinical trials and the effects COVID-19 has had on the black community.

Innovative Trials

- PMLiVE

Merck and Ridgeback’s oral antiviral halves COVID-19 risk of hospitalisation or death

The phase 3 study shows the risk was halved compared to placebo for patients with mild or moderate COVID-19

- PMLiVE

Is COVID-19 yet another barrier to contraceptive access?

In this blog, we’re revisiting the concerns raised in our 2020 MAGNIFI around women’s access to contraceptives in the UK and beyond alongside the influence of the COVID-19 pandemic.

IGNIFI

- PMLiVE

Mitigating misinformation: the importance of effective communication during a public health crisis

By Julie Beeso

Making Digital Trust and Privacy Accessible to Everyone

Mike Cook, CEO of IDENTOS, shares how his company is making digital trust and privacy accessible for patients, healthcare providers, payers, organizations, and connected devices. He also discusses “smart cities”...

Impetus Digital

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links